Any feedback?
Literature summary for 3.4.24.75 extracted from
- Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice (2009), J. Antimicrob. Chemother., 64, 94-100.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | lysostaphin is an effective treatment as well as prophylaxis for Staphylococcus aureus biofilms on indwelling catheters | Staphylococcus simulans |
Cloned(Commentary)
| Cloned (Comment) | Organism |
|---|---|
| recombinant expression in Escherichia coli | Staphylococcus simulans |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Staphylococcus simulans | - |
- |
- |
Purification (Commentary)
| Purification (Comment) | Organism |
|---|---|
| recombinant lysostaphin from Escherichia coli to homogeneity | Staphylococcus simulans |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|
pH Optimum
| pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
|---|---|---|---|
| 7.4 | - |
assay at | Staphylococcus simulans |
General Information
| General Information | Comment | Organism |
|---|---|---|
| additional information | lysostaphin clears Staphylococcus aureus biofilms in vitro and also eradicates established Staphylococcus aureus biofilms on implanted jugular vein catheters in mice, overview | Staphylococcus simulans |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
